What is the 13F Pro Quality Score for ESPR?

13F Pro ranks Esperion Therapeutics, Inc. (ESPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ESPR's current score at https://13fpro.ai/research/ESPR (free sign-up required for the full ranking).

Which hedge funds own the most ESPR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ESPR include BlackRock,, WASATCH ADVISORS, Two Seas Capital. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ESPR as soon as new 13F filings post.

Where does 13F Pro source ESPR data?

All Esperion Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Esperion Therapeutics, Inc. files with the SEC under CIK 1434868. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ESPR in?

Esperion Therapeutics, Inc. (ESPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ESPR research updated on 13F Pro?

ESPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Esperion Therapeutics, Inc.(ESPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1434868 ESPR stock profile & AI dashboard →

13F Pro Quality Score

34.3/100

Rank #2,202 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

80.1/100

Profitability

11.8/100

Balance Sheet

10.2/100

Earnings Quality

30.0/100

Free Cash Flow

12.1/100

Institutional Flow

92.2/100

Revenue Scale

30.4/100

Dilution Risk

37.8/100

ESPR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Esperion Therapeutics, Inc. (ESPR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ESPR at 34.3/100 on a 32-signal composite quality model, placing it at rank #2,202 of 2,879 stocks — the bottom half of the AI-ranked universe. ESPR scores in the top quartile across institutional flow (92.2), revenue growth (80.1). Areas of concern include balance sheet strength (10.2) and profitability (11.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Esperion Therapeutics, Inc. reports quarterly revenue of $80.1M, net income of $-25.2M, free cash flow of $-27.9M. Top institutional holders of ESPR by reported 13-F value include BlackRock,, WASATCH ADVISORS, Two Seas Capital, based on the most recent SEC filings. ESPR trades on the Nasdaq exchange and files with the SEC under CIK 1434868. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ESPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Esperion Therapeutics, Inc. directly from SEC EDGAR. Esperion Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 86 since 2021, currently 34.3 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Esperion Therapeutics, Inc.

Quirks, history, and lore behind ESPR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Michigan.
2
The Numbers
Revenue is in the tens of millions of dollars annually — this is a company still climbing the commercial ladder, not printing blockbuster profits yet.
3
The History
Founded in the early 2000s, it spent years in clinical development before finally winning FDA approval for its lead drug in the cholesterol space.
4
The Secret
Its drugs target LDL cholesterol through a mechanism distinct from statins — specifically aimed at patients who can't tolerate statins or need additional lowering.
5
The Lore
Its approved oral therapy bempedoic acid works by inhibiting an enzyme upstream in the cholesterol synthesis pathway — clever enough to turn heads in cardiology circles.
6
The Giveaway
The maker of Nexletol and Nexlizet — oral, non-statin cholesterol pills — this Ann Arbor biotech's ticker is almost as optimistic as its pipeline.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$80.1M

Net Income

Q1 2026

$-25.2M

Free Cash Flow

Q1 2026

$-27.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+340.3% YoY

$332.3MFY 2024

FY20 $227.5MFY21 $78.4MFY22 $75.5MFY24 $332.3M

Net Income

+77.9% YoY

$-51.7MFY 2024

FY20 $-143.6MFY21 $-269.1MFY22 $-233.7MFY24 $-51.7M

Operating Income

+130.3% YoY

$54.4MFY 2024

FY20 $-121.4MFY21 $-226.7MFY22 $-179.5MFY24 $54.4M

EPS (Diluted)

+92.0% YoY

$-0.28FY 2024

FY20 $-5.23FY21 $-9.31FY22 $-3.52FY24 $-0.28

Total Assets

+38.7% YoY

$343.8MFY 2024

FY20 $353.3MFY21 $381.6MFY22 $247.9MFY24 $343.8M

Total Debt

—FY 2024

FY20 —FY21 —FY22 —FY24 —

Op. Cash Flow

+86.5% YoY

$-23.7MFY 2024

FY20 $-85.2MFY21 $-263.8MFY22 $-174.8MFY24 $-23.7M

Metric	FY 2024	FY 2022	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$332.3M +340.3%	$75.5M -3.8%	$78.4M -65.5%	$227.5M	$0.00	—
Net Income	$-51.7M +77.9%	$-233.7M +13.2%	$-269.1M -87.5%	$-143.6M +28.9%	$-201.8M -20.9%	$-167.0M
Operating Income	$54.4M +130.3%	$-179.5M +20.8%	$-226.7M -86.8%	$-121.4M +40.7%	$-204.6M -21.1%	$-169.0M
EPS (Diluted)	$-0.28 +92.0%	$-3.52 +62.2%	$-9.31 -78.0%	$-5.23	—	—
Total Assets	$343.8M +38.7%	$247.9M -35.0%	$381.6M +8.0%	$353.3M +146.3%	$143.5M -48.4%	$277.8M
Total Debt	—	—	—	—	—	$1.0M
Operating Cash Flow	$-23.7M +86.5%	$-174.8M +33.7%	$-263.8M -209.7%	$-85.2M +42.7%	$-148.6M -13.2%	$-131.3M

AI Insight: ESPR Ratio Trends

Esperion's profitability remains deeply erratic — Q4 2025's 50.6% operating margin appears a one-off spike bracketed by persistent quarterly losses.

• Operating margin swings violently: from -34.0% in Q1 2025 to +50.6% in Q4 2025, then back to -8.2% in Q1 2026.

• TTM operating margin of 18.1% masks ongoing quarterly volatility; net profit margin remains negative at -1.8% on a trailing basis.

• ROA has been negative in seven of eight reported quarters, reaching as low as -70.3% in Q2 2024, signaling persistent asset inefficiency.

⚠ Q4 2025's 36.7% NPM and 53.1% ROA appear anomalous; confirm whether driven by a one-time gain or genuine operational improvement.

⚠ ROE, ROIC, and D/E are entirely absent — leverage and capital return visibility is zero, a meaningful analytical gap.

⚠ Q1 2026 operating margin retreating to -8.2% after Q4 2025's spike suggests no durable margin inflection has taken hold.

Get alerted when ESPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Esperion Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ESPR

BlackRock, Inc.
$48.9M17,852,427 sh
WASATCH ADVISORS LP
$43.2M15,768,897 sh
Two Seas Capital LP
$31.2M11,394,833 sh
ORBIMED ADVISORS LLC
$29.0M10,570,300 sh
VANGUARD CAPITAL MANAGEMENT LLC
$28.6M10,433,760 sh
TWO SIGMA INVESTMENTS, LP
$25.9M9,458,779 sh
MARSHALL WACE, LLP
$19.4M7,075,083 sh
STATE STREET CORP
$19.3M7,055,794 sh
D. E. Shaw & Co., Inc.
$17.9M6,540,785 sh
GEODE CAPITAL MANAGEMENT, LLC
$16.3M5,955,739 sh

Fund	Value	Shares
BlackRock, Inc.	$48.9M	17,852,427
WASATCH ADVISORS LP	$43.2M	15,768,897
Two Seas Capital LP	$31.2M	11,394,833
ORBIMED ADVISORS LLC	$29.0M	10,570,300
VANGUARD CAPITAL MANAGEMENT LLC	$28.6M	10,433,760
TWO SIGMA INVESTMENTS, LP	$25.9M	9,458,779
MARSHALL WACE, LLP	$19.4M	7,075,083
STATE STREET CORP	$19.3M	7,055,794
D. E. Shaw & Co., Inc.	$17.9M	6,540,785
GEODE CAPITAL MANAGEMENT, LLC	$16.3M	5,955,739

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ESPR on your watchlist

Track score changes the day Esperion Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ESPR a good stock to buy?

13F Pro's AI-powered analysis of Esperion Therapeutics, Inc. (ESPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ESPR are available on the ESPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ESPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ESPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Esperion Therapeutics, Inc.'s investment landscape.